Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at firstname.lastname@example.org
Sarah Donahue Highlights Destiny-Breast04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast CancerAugust 1st 2022
Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.
Ripretinib Exhibits Better Tolerability Profile Vs Sunitinib in Advanced GIST TumorsJuly 27th 2022
An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.
Axi-cel Linked To Longer Quality Time Without Toxicity in Patients With R/R LBCLJuly 22nd 2022
A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.
Extended Follow-Up Shows Durable Outcomes, No New Safety Signals With Brexucabtagene Autoleucel in R/R B-ALLJuly 19th 2022
Brexucabtagene autoleucel, a CAR T-cell therapy approved in 2021 for relapsed or refractory B-cell acute lymphoblastic leukemia, showed efficacious results and promising safety data at 2-year follow-up.
Key Advances in Cancer Survivorship Toxicity ManagementJuly 15th 2022
In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Frontline Ribociclib-Related Quality of Life Favorable to Abemaciclib in HR+/HER2- Advanced Breast CancerJuly 15th 2022
Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced MelanomaJuly 13th 2022
Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
Expanded Safety Analysis from CheckMate 648 Shows Tolerability with Frontline Nivolumab Combinations in ESCCJune 29th 2022
Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.
Virtual Planning For Surgical Reconstruction May Improve Outcomes for Patients With Head and Neck CancerJune 29th 2022
Mandible reconstruction and maxilla reconstruction surgeries might be optimized with virtual surgical planning, according to an expert speaker at the 2022 Supportive Care in Cancer Annual Meeting.
Experts Make the Case for Buprenorphine Use in Cancer-Related Pain ManagementJune 28th 2022
Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.
Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer SurvivorsJune 27th 2022
Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.
Patients Receiving PD-1/PD-L1 Inhibitor Therapy More Frequently Experience Secondary Adrenal InsufficiencyJune 17th 2022
A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.
Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian CancerJune 14th 2022
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.